Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Miami
With
Acorda Therapeutics
Subjects with Parkinson's disease will be randomly assigned to two groups. One group will receive Ampyra first for 4 weeks, followed by 2 weeks break and than 4 weeks placebo while the second group will first receive placebo and then Ampyra.
Age
45–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Idiopathic PD with stage Hoehn and Yahr Stage\>2-3 and with gait freezing or postural instability.
On stable dosage dopamine agonist/levodopa, and expected to remain on the same dosage of treatment for the duration of study
Age less than 80, onset of disease at age more than 45.
Able to give consent
You may not be if
Past medical history of seizures,
History of renal insufficiency,
History of cardiac arrhythmia,
Severe arthritis,
Women of childbearing potential,
Cognitive impairment
Age more than 80.
PD patients stage 4 H\&Y
PD patient with recent introduction of dopamine agonist or IMAO B
